Maiwei Biopharmaceutical (688062.SH) signed an exclusive license agreement with Kalexo, with a maximum prepayment and milestone payments of up to $1 billion.

Zh tng cijng APP xn, mi wi shngw (688062.SH) fb gnggo, gngs y Kalexo Bio, Inc. gngs (yxi jinchng Kalexo) ji 2MW7141 xingm xinggun (yxi jinchng xk chnpn) qinsh dji xk xiy (yxi jinchng xk xiy) j yuxin g gqun gumi xiy. Zhtng Finance APP News, Maiweisheng Biology (688062.SH) announced that the company has signed an "Exclusive License Agreement" (hereinafter referred to as the "License Agreement") and a "Preferred Stock Purchase Agreement" with Kalexo Bio, Inc. (hereinafter referred to as "Kalexo") related to the 2MW7141 project (hereinafter referred to as the "licensed product").